Feeds:
Posts
Comments

Archive for the ‘Johnson and Johnson’ Category

*****

TODAY’S NEWS:

We’re in the pre-ASCO oncology news build-up phase. Here’s a brief preview. And even more here.

Does HGH really help athletes? Interesting article – the last paragraph is the kicker.

Whistleblowers (J&J) get a payday. And, allegations about illegal sales practices by Roche with Tamiflu.

RECOMMENDED

eLearning. We know that space inside and out, and we have great partners to recommend. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Karl Schmieder of MessagingLab interviews me about Impactiviti. Plus – the timing is never really “right,” is it? 29 and Counting.

JUST FOR FUN

If this doesn’t make you want to visit South America some day, nothing will!

AND, a pharma spoof – So, What’s your Problem with Gram-Negative Bacteria?

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

*****
TODAY’S NEWS

Sometimes I can’t help but voice a bit of skepticism, especially when it comes to sexual disorder treatments. So, count me as less than convinced about this experimental treatment from Boehringer-IngelheimData from pivotal Phase III clinical trials demonstrate that a higher proportion of pre-menopausal women with Hypoactive Sexual Desire Disorder (HSDD) receiving flibanserin 100mg reported both an improvement in their condition and a meaningful benefit from their treatment, compared to placebomore (the single-question Patient Benefit Evaluation appears to me to be really…ummm…meaningful).

Lung cancer preventer for former smokers? Interesting – A drug approved to treat a range of conditions may also work to prevent lung cancer in people who have given up smoking, U.S. researchers reported on Tuesdaymore

AstraZeneca replaces Nexium sales force with telemarketers. And it works.

J&J‘s recall of OTC products. This is becoming a huge black eye, for a company that managed to keep quite a good reputation over the years. It will be an interesting case study of reputation management and quality improvement, esp. for a company that has been a leader in social media usage in this sector.

RECOMMENDED

Compliance and Diversity. The Impactiviti partner network has the providers you need for corporate training – including diversity, compliance, ethics, and much more! Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Red Meat – maybe this picture isn’t so simple after all. Intuitively, this result is actually not too surprising. AND – Are you in a Museum?

JUST FOR FUN

I only rarely get to see hailstorms. That’s what makes this video particularly awesome. Must be seen to be believed!

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

*****
TODAY’S NEWS

Who is the biggest supplier of prescription drugs in the U.S.? Meet Teva - “The day they get their own plane,” says Ronny Gal, an analyst at Sanford C. Bernstein who tracks Teva and is a devotee of the stock, “is the day I downgrade them.”…more

Insulin pen makers roll out new promos.

From the J&J CEO to all of you – sorry.

Ummm….isn’t the nurse re-using syringes really the heart of the problem here? Lawyers…

Free downloadable report from Epsilon on Pharma and Social Media.

RECOMMENDED

Leadership Training. The Impactiviti network can help you with all your needs for training managers/leaders, finding the optimal suppliers for you. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations. And speaking of leadership, here is a great post from my friend Terry Starbucker on two indispensable traits of great leaders.

PLUS

Looking for courage…in a salesperson.

JUST FOR FUN

Waterfalls. 40 Beautiful examples.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

*****
TODAY’S NEWS

A rough patch for J&Joff-label Topomax promotion; Corporate Integrity Agreement (CIA) means “ride-alongs”; OTC product recalls. Ouch.

Glaxo and Novartis dinged by FDA for potentially misleading promotions. More here on the Novartis situation, which involves Gleevec websites.

Intermune gets major setback for lung treatment – InterMune took its best case for pirfenidone to the FDA, and lost. The agency ruled Tuesday afternoon that the developer would need to mount a new clinical trial for the drug before it could provide a green light for marketingmore

RECOMMENDED

Outsourced Training – Sometimes, you don’t have the staffing to meet all the training needs (short-term or long-term). We can help.  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Moving Beyond Blue – my review of a book by an individual struggling with depression, OCD, anxiety, and more.

JUST FOR FUN

Gorgeous pictures of railway bridges. Lots of ‘em!

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

*****

TODAY’S NEWS

Great news for hepatitis C treatment (and Vertex) – Adding the investigational drug telaprevir to standard treatment for hepatitis C infection cures about half the patients willing to give therapy a second try. That compares to a cure rate of just 14 percent among those who were retreated with the standard regimen, according to researchers at the Duke Clinical Research Institute (DCRI)more

Teva gets approval to market generic versions of two key Merck cardio drugs (Cozaar and Hyzaar).

Sanofi makes a long-term investment into a cool-sounding diabetes treatment (pre-Phase 1).

Is Nuvaring a pinata for plaintiff’s attorneys? – Merck’s Nuvaring contraceptive appears to be headed for the same fate as Bayer’s Yaz pill and Johnson & Johnson’s Ortho Evra contraceptive patch: It’s becoming a pinata for plaintiffs’ lawyers who allege the device is more dangerous than older, equally effective products on the marketmore

RECOMMENDED

eMarketing/PR– We can recommend best-in-class partners/agencies for your needs.  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Social Media – Nine things Pharma should learn about Social Media from Dennis Urbaniak (of Sanofi-Aventis US). And, the finalists for the first Dosie Awards are announced.

JUST FOR FUN

Did you know that Niagara Falls once ran dry? True!

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

As more and more pharmaceutical companies dip their toes into social media, one of the issues that surfaces regularly is this: do you put someONE in charge of a blog and/or Twitter account, or do you make it more anonymous? Or something else?

Let’s discuss this. I’ll put out my thoughts; add yours in the comments.

I’ve always advocated that pharma companies should use social networks to humanize their companies, which means employing human faces and voices – having real, authentic, and effective communicators working these channels. People. Folks you can relate to meet, meet at a conference, carry on backchannel discussions with, etc.

J&J has been very effective with this; Marc Monseau has served effectively as the “voice” of J&J in the socialsphere. Recently, Pfizer (@pfizer_news on Twitter) has updated its Twitter account to include a face and a name – Jennifer Kokell, self-identified as tweeting from Global Corporate Media Relations in NYC. Jennifer works with Ray Kerins, who has been aggressively shaking up the Communications practices at Pfizer, including a healthy push into social media.

But the question comes up – what if a company’s social media presence is too dependent on one person? And here the fine line must be walked – on the one hand, social media is all about individuals and personality and dialogue between people – but companies are not one person. And people move on.

By and large, people don’t want another nameless, faceless monolithic channel in social media – some unnamed drone churning out one-way communications in the name of “the company” who has about as much relational value as a dead fish. So – how to strike the balance?

Here’s one idea for larger companies – have a team presence for your blog and Twitter account. Multiple people – say, 3 or 4 – who contribute posts and tweets about a cross-section of the company’s activities. These would be real people with names, pictures, and off-line appearances – but the team approach would reflect the reality that a company IS made up of diverse individuals, and would also make the social media presence less dependent on a solo individual (reflecting the hit-by-a-bus reality of the non-expendable individual). While J&J’s social presence is spearheaded by Marc Monseau, their corporate blog actually has other contributing authors.

That would be one approach for an “official” social media presence. What about “unofficial” social media representatives? I like what is happening at Novartis, where various individuals such as Brad Pendergraph, Colin Foster, Mark Davis, Erik Hawkinson, Ben Atkins and others tweet as professional and accessible human beings who work at Novartis (thus achieving some humanizing of the company) but who have a unique presence reflecting their personal interests and professional perspectives. In fact, with Novartis, the “unofficial” social media presence has far outstripped progress on its “official” corporate social media footprint.

We’re all still on the learning curve with this stuff and companies are experimenting and evolving. What’s your take? One? Many? None? How can a company project humanity and authenticity without too much solo-representative risk?

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Download free e-book: Getting Started with Social Networking.

Read Full Post »

*****

TODAY’S NEWS

Forbes: Pfizer‘s history of buying pipeline lemons. This does only tell one side of the story, however – Pfizer has also acquired some pretty major hits.

Speaking of flops, a couple of major experimental drugs aren’t looking so hot these days.

FDA taking another look at some bone drugs, in relation to hip fractures – There have long been safety questions — and lawsuits — over whether bone-building drugs like Merck’s Fosamax can actually increase the chance of femur fractures. Today, the FDA said it was going to take another look at the safety issuesmore

Did J&J plan to break the rules with Risperdal? Business Week reports. Plus, Shire gets a “fourfecta” warning letter from the FDA on one marketing promotion.

RECOMMENDED

Meetings/Events/Launches – Looking for creative and successful providers who can help make your off-site events a hit? We’ve got the partners you need in the Impactiviti network. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Nine Simple Steps to Getting Started in Social Media. Good stuff from Dose of Digital blog. For a practical guide on how YOU (as an individual) can put social networking to use building your own Opportunity Network, download my free e-book on that subject.

JUST FOR FUN

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

***

Read Full Post »

*****

TODAY’S NEWS

Big approval news for Gilead Sciences Gilead Sciences Inc., the world’s largest maker of HIV treatments, won U.S. approval of an inhaled antibiotic for lung infections in cystic fibrosis patients. The Food and Drug Administration cleared sales of the medicine, given the brand name Cayston, the company said today in a statement. Outside advisers to the FDA backed the product’s safety and effectiveness in a 15-2 vote on Dec. 10more

What is the future of “personalized medicine”? Probably, it’ll look a lot like this (encouraging story from NY Times). Plus, in a cooperative effort, Eli Lilly, Merck and Pfizer have formed an independent, not-for-profit company Asian Cancer Research Group (ACRG) to accelerate research and ultimately improve treatment for patients affected with the most commonly-diagnosed cancers in Asiamore

Of course, in this industry, there is often a mix of good news and bad – and “bad” usually means bad behavior by people who love dollars above sense: lack of openness at AZ?; secret tapes and GSK (plus, a “fixer” who spiked research?); research fraud by rogue doc; kickbacks and J&J; risk of depression assessment and Eli Lilly (are you alive? then you’re at risk!!!). Reminds me of some prior posts on the Gold-in Rule

Novartis looking to expand even more at East Hanover campus. Including themed food venues!

RECOMMENDED

Marketing Training – Looking for resources for training brand marketing professionals? We know the providers you need. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for vendor recommendations.

PLUS

I’m feeling much safer now. FDA finally comes out against “ear candling“! Next up, perhaps – a prohibition of USB-to-nasal-passage uploads??

JUST FOR FUN

Delightful (and BIG) pictures from Vancouver Olympics. Love the colors in the very first one. From Boston.com’s very nice The Big Picture section.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

Review of this week’s snow-impacted ePharma Summit conference is now up on the blog!

TODAY’S NEWS

Benicar for kiddies – Olmesartan medoxomil (Benicar), approved in 2002 to treat high blood pressure in adults, has been sanctioned by the U.S. Food and Drug Administration to treat the same condition in children aged 6 to 16, drug maker Daiichi Sankyo said Thursdaymore

Ouch. More cuts at The Medicines Co. – Medicines Co said it would cut 43 jobs, or 26 percent of its field-based workforce, by the end of February, and take a related charge of $3.5 million in the first quartermore

Billy Tauzin leaving as head of PhRMA - The head of the influential trade association for drug manufacturers announced Thursday night that he is leaving his job. The development comes amid uncertainty over the fate of President Barack Obama’s health care overhaul, which the drug association had backed after striking a deal with the White House and Senate Democrats to limit costs to the industry in the legislationmore

J&J launches new social media initiatives.

RECOMMENDED

Social Media “listening” training and services – Getting started with a social media “listening” strategy? We can help by putting you in contact with the best providers. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Visual treat - Out-of-this-world coral photos. Yum.

JUST FOR FUN

31 Awesome benches. Oddly amusing!

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

TODAY’S NEWS

Note: if you’re going to engage in questionable marketing practices, documenting it in Powerpoint is probably not a “best practice”! Just saying…

Experiment HIV drug from Merck fails in late-stage studies – Merck & Co  on Wednesday said its experimental HIV treatment vicriviroc proved ineffective in two late-stage studies involving patients who had previously been treated with other HIV medicines...more

Merck diarrhea drug does very well – Merck & Co.’s experimental drug against a germ blamed for increasing rates of deadly diarrhea in U.S. hospitals and nursing homes cut repeat infections by 72 percent, a study in the New England Journal of Medicine saidmore

Orphan drug applications are way up.

Upcoming oral MS drugs are very promising – Study results suggest they are much more effective than expensive “disease modifying” MS drugs such as beta interferon and glatiramer acetate, which have to be injected….more

Top biotech layoffs of 2009.

RECOMMENDED

Curriculum Analysis – We have partners that can analyze your current curriculum to insure it is tightly connected to key strategies and goals, identify gaps and build learning paths that support measurable results for key roles in your organization. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

E-detailing – Pfizer doubles its spending. I expect this trend to accelerate across the industry. It simply makes sense.

JUST FOR FUN

OCD Medication - instructions.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

Older Posts »

Follow

Get every new post delivered to your Inbox.

Join 27 other followers